drugset
drugset / Trial / NCT03849261

Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 in Healthy Adults

NCT03849261 ↗

Phase 1 Unknown 36 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of the clinical trail is to evaluate the pharmacokinetics and safety/tolerability after oral administration of CKD-387 and D635 in healthy adults.

Timeline

Start
2019-01-14
Primary completion
2019-02-01
Completion
2019-02-22

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-387 Unknown — Oral
Subject D635 Unknown — Oral

Indications

type 2 diabetes mellitus